Tianqiang Song

机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0001-8456-9015

发表论文 63 篇 · 总被引 1446 次 · h-index 20

代表论文

• A Dual‐Targeting Biomimetic Nanoplatform Integrates SDT/CDT/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy (2025 · Advanced Science · 被引 30)
• 945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) (2023 · Annals of Oncology · 被引 14)
• 1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial (2025 · Annals of Oncology · 被引 7)
• A LASSO Cox Regression Predictive Model for Patients Undergoing Surgery for Pancreatic Body and Tail Adenocarcinoma Patients: Comparative Long-Term Survival Analysis of Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) (2024 · Annals of Surgical Oncology · 被引 5)
• Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion (2024 · BioScience Trends · 被引 2)
• Comparison of adjuvant treatment for intrahepatic cholangiocarcinoma. (2025 · Journal of Clinical Oncology · 被引 1)